Latest Transformation News

CPP Investments and Goodman Group have launched a A$14 billion partnership to develop data centres across key European markets, marking CPP’s first foray into European digital infrastructure.

VRX Silica Limited has announced a strategic leadership transition with Tony Swiericzuk appointed as CEO, succeeding Bruce Maluish who will step down in 2026 but remain on the board. This move positions VRX to advance its Arrowsmith North silica sand project towards production.

Central Petroleum has secured strategic interests in the Cooper and Otway Basins through binding agreements with ADX Energy, setting the stage for a multi-million dollar expansion and planned drilling campaigns in 2026 and 2027.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.

Riedel Resources has successfully raised approximately $1.78 million through a pro rata entitlement offer and subsequent shortfall placement, positioning the company to advance its Kingman Gold Project.

Gratifii Limited is set to transform its digital marketing and engagement capabilities through the acquisition of New Zealand’s Mosh Digital and the Future Pass digital wallet platform, backed by a $2.5 million capital raise.

Midas Minerals has completed its acquisition of the Otavi Copper Project in Namibia, initiating multiple drilling programs across high-grade deposits and securing strong funding to drive exploration in 2026.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.